Viking Therapeutics Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.22, moving 5.49% from the previous trading session.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) closed at $34.09 in the latest trading session, marking a +2.13% move from the prior day.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) reached $31.86 at the closing of the latest trading day, reflecting a -7.21% change compared to its last close.
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
Viking Therapeutics, Inc. (VKTX) reached $31.99 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug
Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.12, denoting a -9.32% move from the preceding trading day.
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III
Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $35.32, marking a -3.13% move from the previous day.
Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain
VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy players, and the potential GLP-1 monetization upon US FDA approval. The management has also prudently focused on the oral/subcutaneous VK2735 clinical trials, potentially stretching their balance sheet over the next two years of unprofitability before requiring any capital raises. Execution risks persist, due to VKTX's Phase 3 trial completion no earlier than 2027 and commercialization sometime in 2028, along with future dilution risks from negative cash flows.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $36.41, marking a +2.85% move from the previous day.
